Medulloblastoma - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 49 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Medulloblastoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Medulloblastoma - Pipeline Review, H2 2014', provides an overview of the Medulloblastoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Medulloblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Medulloblastoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Medulloblastoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Medulloblastoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Medulloblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Medulloblastoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Medulloblastoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Medulloblastoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Medulloblastoma Overview 6
Therapeutics Development 7
Pipeline Products for Medulloblastoma - Overview 7
Pipeline Products for Medulloblastoma - Comparative Analysis 8
Medulloblastoma - Therapeutics under Development by Companies 9
Medulloblastoma - Therapeutics under Investigation by Universities/Institutes 10
Medulloblastoma - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Medulloblastoma - Products under Development by Companies 14
Medulloblastoma - Products under Investigation by Universities/Institutes 15
Medulloblastoma - Companies Involved in Therapeutics Development 16
Takeda Pharmaceutical Company Limited 16
Novartis AG 17
ThromboGenics NV 18
Stemline Therapeutics, Inc. 19
Conkwest, Inc. 20
Medulloblastoma - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
erismodegib - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
TPI-287 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
TB-403 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
SL-301 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CST-102 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
siomycin A - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
TBX-02 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Medulloblastoma - Recent Pipeline Updates 41
Medulloblastoma - Dormant Projects 45
Medulloblastoma - Product Development Milestones 46
Featured News & Press Releases 46
Feb 28, 2013: ThromboGenics And BioInvent Announce Publication Of Scientific Data On TB-403 In Journal Cell 46
Sep 19, 2011: Researchers Discover Regulatory Protein As Potential Drug Target For Brain Tumors 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables
Number of Products under Development for Medulloblastoma, H2 2014 7
Number of Products under Development for Medulloblastoma - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Medulloblastoma - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 16
Medulloblastoma - Pipeline by Novartis AG, H2 2014 17
Medulloblastoma - Pipeline by ThromboGenics NV, H2 2014 18
Medulloblastoma - Pipeline by Stemline Therapeutics, Inc., H2 2014 19
Medulloblastoma - Pipeline by Conkwest, Inc., H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 29
Medulloblastoma Therapeutics - Recent Pipeline Updates, H2 2014 41
Medulloblastoma - Dormant Projects, H2 2014 45